Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy

British Journal of Cancer

Volumn 99, Issue 6, 2008, Pages 900-910

  Lammers, T ^a,b   Subr, V ^c   Peschke, P ^a   Kuhnlein R ^a   Hennink, W E ^b   Ulbrich, K ^c   Kiessling, F ^a   Heilmann, M ^d   Debus, J ^e   Huber, P E ^a,e   Storm, G ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UTRECHT UNIVERSITY   (Netherlands)

^c INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^d INSERM   (France)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemotherapy; Combined modality therapy; Drug targeting; Nanomedicine; Polymer therapeutics; Radiotherapy

Indexed keywords

COPOLYMER; DOXORUBICIN; DRUG CARRIER; GADODIAMIDE; GADOLINIUM; GEMCITABINE; IODINE 131; N (2 HYDROXYPROPYL)METHACRYLAMIDE;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG RELEASE; DRUG TARGETING; GAMMA SCINTIGRAPHY; HUMAN; HUMAN CELL; MALE; MOLECULAR WEIGHT; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RAT; SOLID TUMOR; TUMOR LOCALIZATION;

ACRYLAMIDES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIAGNOSTIC IMAGING; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GADOLINIUM; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; NANOMEDICINE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RATS; RIBONUCLEOTIDE REDUCTASES; TISSUE DISTRIBUTION;

EID: 51449104513     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604561     Document Type: Article

References (44)

1. Au JL, Jang SH, Zheng J, Chen CT, Song S, Hu L, Wientjes MG (2001) Determinants of drug delivery and transport to solid tumors. J Control Release 74: 31-46
2. Bernier J, Hall EJ, Giaccia A (2004) Radiation oncology: a century of achievements. Nat Rev Cancer 4: 737-747
3. Bilim V (2003) Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr Opin Mol Ther 5: 326-330
4. Davies CdeL, Lundstrom LM, Frengen J, Eikenes L, Bruland SOS, Kaalhus O, Hjelstuen MH, Brekken C (2004) Radiation improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Cancer Res 64: 47-53
5. Dipetrillo T, Milas L, Evans D, Akerman P, Ng T, Miner T, Cruff D, Chauhan B, Iannitti D, Harrington D, Safran H (2006) Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. Am J Clin Oncol 29: 376-379
6. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6: 688-701
7. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA (2004) Cardiac safety of liposomal anthracyclines. Semin Oncol 31: 161-181
8. Feng D, Nagy JA, Pyne K, Hammel I, Dvorak HF, Dvorak AM (1999) Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6: 23-44
9. Fuks Z, Leibel SA, Kutcher G, Mohan R, Ling CC (1991) Three-dimensional conformal treatment: a new frontier in radiation therapy. Important Adv Oncol 151-172
10. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) umor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159
11. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PG, Peters AM, Stewart JS (2000) Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res 6: 4939-4949
12. Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271: 58-65
13. Kiessling F, Heilmann M, Lammers T, Ulbrich K, Subr V, Peschke P, Waengler B, Mier W, Schrenk HH, Bock M, Schad L, Semmler W (2006) Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography. Bioconjug Chem 17: 42-51
14. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66: 6732-6740
15. Kopecek J, Kopeckova P, Minko T, Lu Z (2000) HPMA copolymeranticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 50: 61-81
16. Lammers T, Hennink WE, Storm G (2008) Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99: 392-397
17. Lammers T, Kuhnlein R, Kissel M, Subr V, Etrych T, Pola R, Pechar M, Ulbrich K, Storm G, Huber P, Peschke P (2005) Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release 110: 103-118
18. Lammers T, Peschke P, Kühnlein R, Subr V, Ulbrich K, Debus J, Huber P, Hennink W, Storm G (2007) Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J Control Release 117: 333-341
19. Lammers T, Peschke P, Kühnlein R, Subr V, Ulbrich K, Huber P, Hennink W, Storm G (2006) Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia 8: 788-795
20. Lawrence TS, Eisbruch A, Shewach DS (1997) Gemcitabine-mediated radiosensitization. Semin Oncol 24: S7-28
21. Lee YJ, Galoforo SS, Berns CM, Erdos G, Gupta AK, Ways DK, Corry PM (1995) Effect of ionizing radiation on AP-1 binding activity and basic fibroblast growth factor gene expression in drug-sensitive human breast carcinoma MCF-7 and multidrug-resistant MCF-7/ADR cells. J Biol Chem 270: 28790-28796
22. Li C, Ke S, Wu QP, Tansey W, Hunter N, Buchmiller LM, Milas L, Charnsangavej C, Wallace S (2000) Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 6: 2829-2834
23. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, Haasdyk JE, Dickson KA, Brahmbhatt VN, Pattison ST, James AC, Al Bakri G, Straw RC, Stillman B, Graham RM, Brahmbatt H (2007) Bacterially derived 400nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11: 431-445
24. Maduro JH, Pras E, Willemse PH, de Vries EG (2003) Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 29: 471-488
25. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284
26. Milas L, Mason KA, Hunter N, Li C, Wallace S (2003) Poly(L- glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. Int J Radiat Oncol Biol Phys 55: 707-712
27. Moses MA, Brem H, Langer R (2003) Advancing the field of drug delivery: taking aim at cancer. Cancer Cell 4: 337-341
28. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK (1995) Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 55: 5451-5458
29. Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, Yacoub A, Duigou GJ, Young CS, Grant S, Hagan MP, Ellis E, Fisher PB, Dent P (2001) Ionizing radiation modulates vascular endothelial growth factor expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 25: 3266-3280
30. Park JW, Benz CC, Martin FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31(S13): 96-205
31. Peschke P, Klein V, Wolber G, Friedrich E, Hahn EW (1999) Morphometric analysis of bromodeoxyuridine distribution and cell density in the rat Dunning prostate tumor R3327-AT1 following treatment with radiation and/or hyperthermia. Histol Histopathol 14: 461-469
32. Rapoport N, Gao Z, Kennedy A (2007) Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 99: 1095-1106
33. Rihova B, Kubackova K (2003a) Clinical implications of N-(2-hydroxypropyl)-methacrylamide copolymers. Curr Pharm Biotechnol 4: 311-322
34. Rihova B, Strohalm J, Prausova J, Kubackova K, Jelinkova M, Rozprimova L, Sirova M, Plocova D, Etrych T, Subr V, Mrkvan T, Kovar M, Ulbrich K (2003b) Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J Control Release 91: 1-16
35. Rowell NP, O'rourke NP (2004) Concurrent chemoradiotherapy in nonsmall cell lung cancer. Cochrane Database Syst Rev CD002140
36. Samaniego F, Markham PD, Gendelman R, Watanabe Y, Kao V, Kowalski K, Sonnabend JA, Pintus A, Gallo RC, Ensoli B (1998) Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 152: 1433-1443
37. Seiwert TY, Salama JK, Vokes EE (2007) The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4: 86-100
38. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436: 568-572
39. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145- 160
40. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5: 83-94
41. Vokes EE, Weichselbaum RR (1990) Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 8: 911-934
42. Wiedenmann N, Valdecanas D, Hunter N, Hyde S, Buchholz TA, Milas L, Mason KA (2007) 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res 13: 1868-1874
43. Yeung TK, Hopewell JW, Simmonds RH, Seymour LW, Duncan R, Bellini O, Grandi M, Spreafico F, Strohalm J, Ulbrich K (1991) Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl) methacrylamide conjugates: and experimental study in the rat. Cancer Chemother Pharmacol 29: 105-111
44. Znati CA, Rosenstein M, Boucher Y, Epperly MW, Bloomer WD, Jain RK (1996) Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res 56: 964-968